A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

(2010) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies

(2010) Armin Wolf et al.   LEUKEMIA RESEARCH

Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale

(2010) Beth A. Rose et al.   PHYSIOLOGICAL REVIEWS

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

(2010) Kevin J. French et al.   TOXICOLOGIC PATHOLOGY

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

(2009) Risto Kerkela et al.   CTS-Clinical and Translational Science

Fishing for the genetic basis of cardiovascular disease

(2009) T. Dahme et al.   Disease Models & Mechanisms

Heart failure associated with sunitinib malate

(2008) Aarif Y. Khakoo et al.   CANCER

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Modeling Cardiovascular Disease in the Zebrafish

(2008) Timothy J.A. Chico et al.   TRENDS IN CARDIOVASCULAR MEDICINE